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Background-—Mitochondrial reactive oxygen species (ROS) are associated with metabolic heart disease (MHD). However,
the mechanism by which ROS cause MHD is unknown. We tested the hypothesis that mitochondrial ROS are a key mediator of
MHD.
Methods and Results-—Mice fed a high-fat high-sucrose (HFHS) diet develop MHD with cardiac diastolic and mitochondrial
dysfunction that is associated with oxidative posttranslational modiﬁcations of cardiac mitochondrial proteins. Transgenic mice
that express catalase in mitochondria and wild-type mice were fed an HFHS or control diet for 4 months. Cardiac mitochondria
from HFHS-fed wild-type mice had a 3-fold greater rate of H2O2 production (P=0.001 versus control diet fed), a 30% decrease in
complex II substrate–driven oxygen consumption (P=0.006), 21% to 23% decreases in complex I and II substrate–driven ATP
synthesis (P=0.01), and a 62% decrease in complex II activity (P=0.002). In transgenic mice that express catalase in mitochondria,
all HFHS diet–induced mitochondrial abnormalities were ameliorated, as were left ventricular hypertrophy and diastolic
dysfunction. In HFHS-fed wild-type mice complex II substrate–driven ATP synthesis and activity were restored ex vivo by
dithiothreitol (5 mmol/L), suggesting a role for reversible cysteine oxidative posttranslational modiﬁcations. In vitro site-directed
mutation of complex II subunit B Cys100 or Cys103 to redox-insensitive serines prevented complex II dysfunction induced by ROS
or high glucose/high palmitate in the medium.
Conclusion-—Mitochondrial ROS are pathogenic in MHD and contribute to mitochondrial dysfunction, at least in part, by causing
oxidative posttranslational modiﬁcations of complex I and II proteins including reversible oxidative posttranslational modiﬁcations
of complex II subunit B Cys100 and Cys103. ( J Am Heart Assoc. 2016;5:e002555 doi: 10.1161/JAHA.115.002555)
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O ne-third of Americans have obesity-related metabolicsyndrome with type 2 diabetes, hypertension, and
dyslipidemia.1–3 An important consequence of metabolic
syndrome is metabolic heart disease (MHD), which is
associated with left ventricular (LV) hypertrophy, diastolic
dysfunction, and impaired cardiac energetics.4–7 We previ-
ously showed that feeding mice a high-fat, high-sucrose
(HFHS) diet for 8 months leads to obesity, metabolic
syndrome, and a cardiac phenotype typical of MHD with LV
hypertrophy, diastolic dysfunction, and cardiac mitochondrial
dysfunction.8,9
Several ﬁndings in HFHS-fed mice suggest a central role
for reactive oxygen species (ROS) in the development of MHD.
Markers of oxidative stress are increased in the myocardium,8
and oxidative posttranslational modiﬁcations (OPTMs) are
found in multiple target proteins, many of which are in the
mitochondria.10 A role for ROS is further supported by our
demonstration in isolated mitochondria from HFHS-fed mice
that there is impaired complex II–driven ATP generation,
which is restored ex vivo by dithiothreitol (DTT).9 The cardiac
phenotype of hypertrophy and diastolic dysfunction is also
prevented by polyphenols,8 which may exert antioxidant
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effects. Finally, ROS production is increased in isolated
cardiac mitochondria from these mice,9 suggesting that
mitochondria may be a source of ROS with HFHS feeding.
Together, these observations led to our thesis that
mitochondrial ROS play a key role in mediating MHD in
HFHS-fed mice. These observations, though suggestive, are
circumstantial. A primary goal of the present study was to test
the thesis in vivo using an intervention that is speciﬁc for
mitochondrial ROS. Accordingly, in mice fed a HFHS diet for
4 months, we studied the effects of decreasing mitochondrial
ROS by transgenic expression of mitochondrial catalase on (1)
ATP production and respiration in isolated cardiac mitochon-
dria and (2) cardiac structural and functional remodeling. The
mechanistic role of cysteine oxidation was assessed ex vivo in
isolated mitochondria by examining the effects of exposure to
a reducing environment on complex II oxidation and function.
The role of speciﬁc oxidative cysteine modiﬁcations of
complex II in mediating dysfunction was assessed in vitro
by site-directed mutation to redox-insensitive serines in
HEK-293T cells exposed to ROS or high glucose/high
palmitate in the medium.
Methods
Experimental Animals
Mitochondrially targeted catalase overexpressing (mCAT) and
wild-type (WT) littermate control mice (C57BL/6NJ back-
ground) 9 weeks of age were fed ad libitum either a control
chow diet (CD; Research Diets, product No. D09071703, 10%
kcal lard, 0% sucrose) or an HFHS diet (Research Diets,
product No. D09071702; 58% kcal lard, 13% kcal sucrose) for
4 months. mCAT mice were obtained from the Jackson
Laboratory [strain: B6.Cg-Tg(CAG-OTC/CAT)4033Prab/J;
stock No. 016197]. These mice were originally developed
by Dr Peter Rabinovitch’s group (University of Washington),
and their characteristics are published.11 Diet compositions
were matched for caloric value (Table S1). Mice were weighed
and killed at the end of the study. A total of 20 animals were
used for the experiments: WT/CD (n=6), WT/HFHS (n=4),
mCAT/CD (n=5), and mCAT/HFHS (n=5). HFHS diet caused
obesity to similar extents in WT and mCAT mice (Figure S1).
We have previously shown that HFHS diet leads to insulin
resistance by 2 months on the diet with hyperglycemia and
elevated Homeostatic Model Assessment of Insulin Resitance
(HOMA-IR),12 while plasma free fatty acids and triglycerides
are not elevated up to 8 months on the diet.8
The protocol was approved by the Institutional Animal Care
and Use Committee at Boston University School of Medicine.
A 4-month HFHS diet duration was chosen to avoid the
potential confounding effects of renal impairment and hyper-
tension that appear after 4 months on the HFHS diet.8,12
Two-Dimensional and M-Mode Echocardiography
LV dimensions and systolic function were measured in
nonanesthetized mice with use of an Acuson Sequoia C-256
echocardiograph machine equipped with a 15-MHz linear
transducer (model 15L8), as we have previously described.8
Brieﬂy, the heart was imaged in the 2-dimensional parasternal
short-axis view, and an M-mode echocardiogram of the mid-
ventricle was recorded at the level of papillary muscles.
Anterior wall thickness, posterior wall thickness, and LV end-
diastolic and end-systolic dimensions were measured from
the M-mode image. LV fractional shortening was calculated as
follows: [(end-diastolic dimensionend-systolic dimension)/
end-diastolic dimension9100].
Doppler Echocardiography
LV diastolic function was assessed with transmitral and
tissue Doppler echocardiography with the use of a VisualSon-
ics Vevo 770 high-resolution imaging system equipped with a
30-MHz RMV-707B transducer.8 Brieﬂy, mice were anes-
thetized with isoﬂurane via facemask at a concentration of
2.5% for induction and then 1.5% for maintenance. Pulsed-
wave Doppler images were collected in the apical 4-chamber
view to record the mitral Doppler ﬂow spectra. Peak early (E)
and late (A) mitral inﬂow velocities, E/A ratio, deceleration
time of early ﬁling, and isovolumetric relaxation time were
measured. Tissue Doppler images were collected in the
parasternal short-axis view, and myocardial peak early
diastolic velocity was measured. Doppler spectra were
recorded for 12 to 14 cardiac cycles, from which at least 5
consecutive cardiac cycles were selected, and the values
were averaged in accordance with the American Society of
Echocardiography guidelines.13 Data analysis was performed
ofﬂine with the use of a customized version of Vevo 770
Analytic software.
Mitochondrial Isolation
Heart mitochondria were isolated as previously described by
us with minor modiﬁcations.9,14,15 All steps were performed
at 4°C. Brieﬂy, tissues were rinsed in a buffer containing
100 mmol/L KCl, 5 mmol/L EGTA, and 5 mmol/L HEPES, pH
7.0, and thereafter homogenized in 2 mL of HES buffer
(HEPES 5 mmol/L, EDTA 1 mmol/L, sucrose 0.25 mol/L, pH
7.4 adjusted with KOH 1 mol/L) by using a Teﬂon-on-glass
electric homogenizer. The homogenate was centrifuged at
500g for 10 minutes at 4°C. The supernatant was then
centrifuged at 9000g for 15 minutes at 4°C, and the
mitochondrial pellet was resuspended in 100 lL of HES
buffer with 0.3% of BSA fatty acid free. Protein was quantiﬁed
with the use of BCA (Pierce), and the value of HES-BSA buffer
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alone was subtracted. This isolation method captures pre-
dominantly subsarcolemmal mitochondria.
Mitochondrial H2O2 Production
Mitochondrial H2O2 production was measured by using the
Amplex Ultra Red horseradish peroxidase method (Invitrogen)
as we described previously with minor modiﬁcations.9 This
assay is based on the horseradish peroxidase (2 units/mL)
H2O2-dependent oxidation of nonﬂuorescent Amplex Ultra
Red (50 lmol/L) to ﬂuorescent resoruﬁn red. In short, 10 lg
mitochondria was diluted in 50 lL of reaction buffer
(125 mmol/L KCl, 10 mmol/L HEPES, 5 mmol/L MgCl2,
2 mmol/L K2HPO4, pH 7.44) to determine complex I
(pyruvate/malate, 5 mmol/L) or complex II (succinate,
5 mmol/L)–driven H2O2 production with and without inhi-
bitor (rotenone 2 lmol/L). Mitochondrial H2O2 production
was measured after the addition of 50 lL of reaction buffer
containing horseradish peroxidase and Amplex Ultra Red.
Fluorescence was followed at an excitation wavelength of
545 nm and an emission wavelength of 590 nm for 20 min-
utes. The slope of the increase in ﬂuorescence is converted
to the rate of H2O2 production with the use of a standard
curve. All of the assays were performed at 25°C. The results
are reported as picomoles per minute per milligrams of
protein.
ATP Production in Isolated Mitochondria
ATP synthesis rates in isolated heart mitochondria were
determined by using the luciferin/luciferase–based ATP
Bioluminescence Assay Kit CLS II (Roche) as we previously
described with minor modiﬁcations.9 In short, 10 lg of heart
mitochondria was suspended in 75 lL of buffer A
(125 mmol/L KCl, 10 mmol/L HEPES, 5 mmol/L MgCl2,
and 2 mmol/L K2HPO4, pH 7.44) to determine complex I
(pyruvate/malate, 5 mmol/L ﬁnal) or complex II (succinate,
5 mmol/L ﬁnal)–driven ATP synthesis. Following standard
practice, succinate-driven ATP generation was measured in
the presence of complex I inhibitor rotenone (2 lmol/L) to
avoid the reverse electron transfer effect.16 The assays were
performed in the presence and absence of DTT 5 mmol/L.
Measurements with substrates were repeated in the pres-
ence of oligomycin, an inhibitor of ATP synthase, to
determine the rates of nonmitochondrial ATP production.
The background of the assay was determined with mito-
chondria alone. The measurements for all samples were
started simultaneously by adding 75 lL of luciferin/lu-
ciferase buffer containing 1 mmol/L ADP (0.5 mmol/L ﬁnal).
The initial slope of the increase in ATP-supported luciferase
chemiluminescence was used to determine the rate of ATP
production after subtraction of the background and nonmi-
tochondrial values. With use of an ATP standard provided in
the kit, the slopes were converted in nanomoles per minute
per milligrams of protein.
Mitochondrial Electron Transport Chain Complex
II Activity
Complex II enzyme activity of isolated mitochondria was
measured by using a microplate assay kit (Abcam/Mito-
sciences ab109908/MS241), as we previously described.9 In
this assay kit, complex II is immunocaptured within the wells
of the microplate. The production of ubiquinol by complex II is
coupled to the reduction of the dye DCPIP (2,6-diclorophe-
nolindophenol), and decreases in its absorbance at 600 nm
are measured spectrophotometrically. The assay is performed
in the presence of succinate as a substrate. The assay was
performed in the presence and absence of 5 mmol/L DTT.
Enzymatic activity was normalized to mitochondrial protein
concentration.
Mitochondrial Oxygen Consumption Rate
Oxygen consumption rates were monitored by using a
Seahorse XF24 oxygen ﬂux analyzer as we previously
described.14,15 Isolated mitochondria were loaded in a 24-
well Seahorse plate on ice (5–12.5 lg/well) and 500 lL of
ice-cold mitochondrial assay solution (MAS: 70 mmol/L
sucrose, 220 mmol/L mannitol, 5 mmol/L KH2PO4,
5 mmol/L MgCl2, 2 mmol/L HEPES, 1 mmol/L EGTA, 0.3%
BSA fatty acid free, pH 7.4) were added on top. The 4
sequential injection ports of the Seahorse cartridge contained
the following: port A, 50 lL of 109 substrate (complex I:
50 mmol/L pyruvate and 50 mmol/L malate; complex II:
50 mmol/L succinate and 20 lmol/L rotenone in MAS) and
2.5 mmol/L ADP; port B, 55 lL of 20 lmol/L oligomycin;
port C, 60 lL of 40 lmol/L Carbonyl cyanide-4-(triﬂuoro-
methoxy)phenylhydrazone (FCCP); and port D 65 lL of
40 lmol/L antimycin A. State III was determined after port
A injection, state IV after port B, and uncoupled after port C.
Antimycin A was used as a control because it blocks the
electron transport chain to minimize mitochondrial oxygen
consumption. The results are reported as qmol oxygen per
minute per microgram of protein.
Immunoblotting for Mitochondrial Proteins
Immunoblots were performed on frozen LV that was homog-
enized in tissue lysis buffer (HEPES, pH 7.4, 20 mmol/L, B-
glycerol phosphate 50 mmol/L, EGTA 2 mmol/L, DTT
1 mmol/L, NaF 10 mmol/L, NaVO4 1 mmol/L, Triton X-100
1%, glycerol 10%, and 1 protease inhibitor complete mini
tablet, EDTA free, 20 mL [Roche]). Total protein (25 lg) was
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separated via sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and transferred to polyvinylidene ﬂuoride
membranes. Blots were incubated with mouse total OXPHOS
Rodent WB Antibody cocktail (containing 5 antibodies, 1 each
against complex I subunit [NDUFB8], complex II subunit B
[SDHB], complex III core protein 2 [UQCRC2], complex IV
subunit I [MTCO1], and complex V alpha subunit [ATP5A])
(Abcam; ab110413), anti-VDAC1 (Abcam; ab15895), and anti-
GAPDH (Abcam; ab8245) and detected with the use of the
Licor Odyssey 2-color infrared imaging system.
Biotin Switch Assay
Labeling with biotin iodoacetamide (BIAM; Life Technologies;
B-1591) was used in a biotin switch assay to detect reversibly
oxidized cysteines, as we previously described with minor
modiﬁcations.9,17 Freshly isolated LV sections were immedi-
ately snap-frozen and stored in liquid nitrogen. Tissue was
thawed and lysed in RIPA buffer containing 100 mmol/L N-
ethylmaleimide (NEM) to block all free thiols and prevent
further oxidation. Excess NEM was removed by passing the
lysates over Zeba spin columns. NEM-labeled proteins are
treated with 5 mmol/L DTT at room temperature for 15 min-
utes to reduce reversible oxidations to free thiols and again
column cleaned to eliminate DTT. Samples are incubated with
4 mmol/L BIAM for 2 hours at room temperature in the dark,
labeling any reactive free thiols that were previously oxidized.
BIAM-labeled proteins are isolated from total protein pool with
the use of streptavidin magnetic beads (50 lL) for 1 hour at
room temperature in the dark, washed, and cleaved from
beads by boiling in 30 lL of 29 nonreducing Laemmli buffer
for 10 minutes. Entire BIAM-labeled and unlabeled protein
fractions are subjected to Western blotting and probed with
anti-SDHB (Abcam; ab14714) antibodies, and bands were
detected by using near-infrared dye-conjugated secondary
antibodies and quantiﬁed with the Licor Odyssey 2-color
infrared imaging system. Ratio of labeled to total (labeled plus
unlabeled) proteins represents percentage of reversibly oxi-
dized cysteines in SDHB.
Construction of SDHB Cysteine Mutants and
Expression in HEK-293T Cells
Full-length mouse SDHB construct in pCMV-sport6 was
obtained from American Type Culture Collection (ATCC;
MGC: 19177; IMAGE: 4225025) and used as the template
for site-directed mutagenesis. The Cys?Ser mutants were
prepared by introducing a single base exchange (Cys100Ser,
TGT?TCT; Cys103Ser, TGT?TCT; Cys115Ser, TGT?TCT)
with use of the QuikChange II XL site-directed mutagenesis
kit. Mutants were conﬁrmed by DNA sequencing (Tufts
Medical Center, Sequencing Core, Boston, MA). Constructs
or empty vector, serving as control, were transfected into
HEK-293T cells by using polyethyleneimine “MAX” transfec-
tion reagent (Polysciences, Inc).
In Vitro Exposure to H2O2 or High-Glucose/High-
Palmitate Medium
Cells were then cultured for an additional 42 to 48 hours in
DMEM supplemented with 10% fetal bovine serum. At the end
of that period, cells were treated with either 500 lmol/L H2O2
or vehicle for 10 minutes. In other experiments, cells were
cultured for 14 hours in high-glucose/high-palmitate (HGHP)
medium (25 mmol/L glucose, 0.4 mmol/L palmitic acid,
0.67% BSA) or control media (5 mmol/L glucose, 0.67%
BSA), as previously described.17 Cells were then lyzed, and
complex II activity was measured as described earlier with the
use of the Abcam/Mitosciences kit ab109908/MS241.
Statistical Analysis
Data are presented as meanSEM. Comparisons between
groups were performed by using 1-way ANOVA with Bonfer-
roni posttests for multiple comparisons. All statistical analy-
ses were performed with GraphPad Prism version 6 software
(GraphPad Software Inc). A value of P<0.05 was considered
statistically signiﬁcant.
Results
Mitochondrial H2O2 Production Is Increased After
4 Months of HFHS Diet and Corrected in mCAT
Mice
In cardiac mitochondria from WT mice fed an HFHS diet
versus the CD, H2O2 production was increased with either
complex I (pyruvate+malate; Figure 1A) or complex II (succi-
nate+rotenone; Figure 1B) substrates. The HFHS-induced
increases in H2O2 production with both complex I and II
substrates were prevented in mCAT mice (Figure 1).
Effects of HFHS Diet and mCAT Expression on
Maximal ATP Synthesis Rate
In mitochondria from HFHS-fed WT mice, the maximal rates of
ATP synthesis were decreased by 21% and 23% for complex I
(Figure 2A) and complex II (Figure 2B) substrates, respec-
tively. The HFHS-induced decreases in ATP synthesis rates for
complex I and complex II substrates were both prevented in
mCAT mice (Figure 2). The HFHS-induced decreases in
complex I and II function were not associated with a change
in the protein expression of the representative subunits of
complexes I, II, III, IV, or V (Table S2). Thus, decreased
DOI: 10.1161/JAHA.115.002555 Journal of the American Heart Association 4
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complex I and II ATP production in HFHS-fed mice is not the
result of decreased expression of complex I or II proteins.
Effects of HFHS Diet and mCAT on Mitochondrial
Oxygen Consumption
To further assess the mechanism responsible for decreased
ATP production with HFHS feeding, oxygen consumption rate
was measured in isolated mitochondria by using a Seahorse
XF24 oxygen ﬂux analyzer. In WT mice, complex I–mediated
respiration linked to maximal ATP synthesis rate (state III) and
proton leak (state IV) both tended to be lower in HFHS-fed
mice but did not reach statistical signiﬁcance (Figure 3A and
3B). Likewise, complex I substrate state III and IV oxygen
consumption rates tended to be higher in HFHS-fed mCAT
(versus WT) mice but did not reach statistical signiﬁcance
(Figure 3A and 3B). Both complex II–mediated state III and
state IV, oxygen consumption rates were signiﬁcantly
decreased in mitochondria from HFHS-fed WT mice, and the
HFHS-mediated decreases in both state III and state IV
oxygen consumption rates were prevented in mCAT mice
(Figure 3C and 3D). The parallel decreases in state III and IV
respiration with HFHS feeding suggests that the observed
decreases in complex I and II–mediated ATP production are
the result of impaired electron transport chain function rather
than proton leak. The ability of mCAT to correct both ATP
production and respiration suggests that catalase-sensitive
Figure 1. Increased cardiac mitochondrial H2O2 production in
high-fat high-sucrose (HFHS) diet–fed mice is prevented by
transgenic expression of mitochondrial catalase (mCAT). The
mitochondrial H2O2 production rate is increased in cardiac
mitochondria from wild-type (WT) but not mCAT mice. A, H2O2
production rate with a complex I substrate (5 mmol/L pyru-
vate+5 mmol/L malate); (B) H2O2 production rate with a complex
II substrate (5 mmol/L succinate) and inhibition of reverse
electron transport (2 lmol/L rotenone). Values are meanSEM;
n=4 to 5; **P<0.01 vs WT control diet (CD); ***P<0.001 vs WT
CD; ##P<0.01 vs WT HFHS; ###P<0.001 vs WT HFHS.
Figure 2. Decreases in complex I and II substrate–driven
cardiac mitochondrial ATP synthesis rates in high-fat high-sucrose
(HFHS) diet–fed mice are prevented in mitochondrial catalase
(mCAT) mice. Cardiac mitochondrial complex I and II substrate–
driven ATP synthesis rates are decreased in HFHS-fed wild-type
(WT) but not mCAT mice. A, Complex I substrate–driven ATP
synthesis rate (5 mmol/L pyruvate+5 mmol/L malate). B, Com-
plex II substrate–driven ATP synthesis rate (5 mmol/L succi-
nate+2 lmol/L rotenone). Values are meanSEM; n=4 to 6;
**P<0.01 vs WT control diet (CD); ***P<0.001 vs WT CD;
##P<0.01 vs WT HFHS.
DOI: 10.1161/JAHA.115.002555 Journal of the American Heart Association 5
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ROS mediates the observed electron transport chain dys-
function. To control for mitochondrial integrity we derived
respiratory control ratios for state III/IV oxygen consumption
rate values. There were no differences in respiratory control
ratios between CD, HFHS, or mCAT groups (Figure S2).
Differential Effects of DTT on Complex I and II–
Mediated ATP Production
We previously observed that with 8 months of HFHS feeding,
complex II dysfunction is reversed by DTT ex vivo, while
complex I dysfunction is not.9 Likewise, in mitochondria from
HFHS-fed WT mice, preincubation with DTT (5 mmol/L) had
no effect on complex I substrate–mediated ATP synthesis
(Figure S3A) but restored complex II substrate–mediated ATP
synthesis to that of WT CD-fed mice (Figure S3B). In
mitochondria from mCAT mice, DTT had no effect on either
complex I or complex II substrate–mediated ATP synthesis
rate, regardless of diet (Figure S4A and S4B). These
observations suggest that mCAT fully normalizes complex I
and II function in HFHS-fed mice.
The HFHS Diet-–Induced Decrease in Complex II
Activity Is Reversible
We further assessed complex II directly by measuring the
reduction of ubiquinone to ubiquinol. In WT mice, HFHS feeding
decreased complex II activity by 62% (Figure 4A). DTT com-
pletely restored complex II activity inHFHS-fedmice (Figure 4A).
The HFHS-induced decrease in complex II activity was prevented
in mCAT mice (Figure 4B), and accordingly, DTT had no further
effect on complex II activity in HFHS-fedmCATmice (Figure 4C).
These observations conﬁrm that the HFHS feeding–induced
decrease in complex II function, as reﬂected by ATP production,
is prevented by mCAT in vivo and reversed by DTT ex vivo.
HFHS Feeding Causes Reversible Cysteine
OPTMs in Complex II
We previously used iodoacetamide-based cysteine-reactive
tandem mass tags to identify 3 cysteines in SDHB that
undergo reversible oxidation with HFHS feeding for
8 months.9,10 To determine whether reversible cysteine
Figure 3. Decreased cardiac mitochondrial maximal and uncoupled oxygen consumption in high-fat high-
sucrose (HFHS) diet–fed mice is normalized in mitochondrial catalase (mCAT) mice. A, Complex I substrate–
driven maximal oxygen consumption rate (state III). B, Complex I substrate–driven uncoupled (oligomycin
2 lmol/L) oxygen consumption rate (state IV). C, Complex II substrate–driven maximal oxygen
consumption rate (state III). D, Complex II substrate–driven uncoupled (oligomycin 2 lmol/L) oxygen
consumption rate (state IV). Values are meanSEM; n=4 to 6; *P<0.05 vs wild-type (WT) control diet (CD);
**P<0.01 vs WT CD; #P<0.05 vs WT HFHS.
DOI: 10.1161/JAHA.115.002555 Journal of the American Heart Association 6
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oxidation occurs in the SDHB subunit of complex II with HFHS
feeding for only 4 months, we performed a biotin-switch
assay in LV homogenates. Free thiols were blocked with
N-ethylmaleimide; reversibly oxidized thiols were then
reduced with DTT (as in the ATP and complex II activity
assays), labeled with BIAM and immunoblotted for SDHB. The
quantity of reversibly oxidized thiols in SDHB was increased
by HFHS feeding, and this increase was prevented in mCAT
mice (Figure 5). Thus, ≥1 reversible OPTMs of complex II
subunit B are associated with HFHS feeding–induced complex
II dysfunction and are prevented by mCAT.
SDHB Redox-Insensitive Mutants Protect
Complex II Activity From ROS- and HGHP-
Mediated Inhibition
To test whether cysteine OPTMs could mediate the complex II
inhibition in HFHS-fed mice, we used HEK-293T cells as a
model system. Exposure of HEK cells to H2O2 (500 lmol/L,
Figure 4. Decreased cardiac mitochondrial complex II activity
in high-fat high-sucrose (HFHS) diet–fed mice is corrected by
exposure to dithiothreitol (DTT; 5 mmol/L) ex vivo and
prevented by overexpression of mitochondrial catalase (mCAT)
in vivo. A, In wild-type (WT) mice, complex II activity assessed
by the reduction of ubiquinone to ubiquinol is decreased by
HFHS feeding and restored by exposure to DTT (5 mmol/L)
ex vivo. B, In mCAT mice, the HFHS-induced decrease in
complex II activity is prevented. C, In mCAT mice, DTT
exposure ex vivo has no effect irrespective of diet. Values
are meanSEM; n=4 to 5; ***P<0.001 vs WT control diet
(CD); ###P<0.001 vs WT HFHS.
WT CD WT HFHS mCAT HFHSmCAT CD
37kD
SDHB 30kD







Figure 5. Reversible cysteine oxidative posttranslational mod-
iﬁcations (OPTMs) of cardiac mitochondrial complex II subunit B
(succinate dehydrogenase B; SDHB) are increased in high-fat high-
sucrose (HFHS) diet–fed wild-type (WT) mice and prevented in
mitochondrial catalase (mCAT) mice. A biotin switch assay was
used to detect reversibly oxidized cysteines on SDHB. A,
Representative blot in which “I” represents protein labeled by
the antibody for SDHB and “Ox” represents the portion of total
protein containing a reversible cysteine OPTM. B, Bar graph
showing the mean values for the ratio of oxidized (Ox) to total
(I+Ox) SDHB, reﬂecting the proportion of reversibly oxidized
cysteines. MW, molecular weight. Values are meanSEM; n=4 to
5; ***P<0.001 vs WT control diet (CD); ###P<0.001 vs WT HFHS.
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10 minutes) caused an 55% decrease complex II activity,
which was restored by the ex vivo addition of (DTT 5 mmol/L)
(Figure 6A), consistent with the DTT-reversible inhibition of
complex II function that we observed with HFHS feeding (see
Figure 4). Based on our prior observation that Cys100, Cys103,
and Cys115 undergo reversible oxidation in HFHS-fedmice,9 we
used site-directed mutagenesis to generate SHDB constructs in
which these cysteines are replaced by serine and therefore no
longer redox sensitive. Baseline complex II activity in the HEK
cells transfected with SDHBmutants was not different from that
in HEK cells transfected with a control empty vector (Figure 6B
through 6D). HEK cells transfected with the Cys100Ser and
Cys103Ser SDHB mutants were each protected from the H2O2-
mediated decrease in complex II activity (Figure 6B and 6C),
whereas HEK cells transfected with Cys115Ser mutant
remained susceptible (Figure 6D).
To further assess the relevance of the effects of H2O2 on
complex II activity, HEK-293T cells were incubated in media
containing high concentrations of glucose (25 mmol/L) and
palmitate (0.4 mmol/L). As with H2O2, there was an 60%
decrease in complex II activity, which was fully reversed by
DTT exposure ex vivo (Figure 7A). As with H2O2, the HGHP-
mediated decrease in complex II activity was prevented in
cells expressing the Cys100Ser and Cys103Ser mutants but
not Cys115Ser mutant (Figure 7B through 7D).
mCAT Prevents HFHS Diet–Mediated LV
Hypertrophy and Diastolic Dysfunction
As we previously observed,8 WT mice fed an HFHS diet
developed LV hypertrophy as reﬂected by increased LV
weight/tibia length (Table) and increased LV wall thickness
(Table; Figure 8A). The HFHS diet–induced increase in LV wall
thickness in WT mice (0.270.02 mm) was less in mCAT mice
(0.090.008 mm; P<0.01 versus WT HFHS) (Figure 8A). Like-
wise, although the heart weight tends to be increased in mCAT
Figure 6. Oxidation of succinate dehydrogenase B (SDHB) Cys100 and Cys103 inhibits mitochondrial
complex II activity. Exposure of cells to H2O2 (500 lmol/L, 10 minutes) decreased complex II activity,
measured as per Figure 4, in HEK 293T cells. SDHB in which Cys100Ser (C100S), Cys103Ser (C103S), or
Cys115Ser (C115S) was mutated to a redox-insensitive serine was expressed in HEK 293T cells, and
complex II activity was measured after exposure to H2O2. A, H2O2 decreased complex II activity in HEK cells
transfected with empty vector (CTRL), and activity was restored after incubation of cell lysate with
dithiothreitol (DTT; 5 mmol/L). B, Expression of the SDHB C100S mutant prevents the H2O2-mediated
decrease in complex II activity. C, Expression of the SDHB C103S mutant prevents the H2O2-mediated
decrease in complex II activity. D, Expression of the SDHB C115S mutant has no effect on the H2O2-
mediated decrease in complex II activity. Values are meanSEM; n=5; **P<0.01 vs CTRL; ##P<0.01 vs
CTRL+H2O2;
###P<0.001 vs CTRL+H2O2.
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mice (versus WT) on the CD, the HFHF diet-induced increase in
LVweight/tibia length inWTmice (1.60.07 mg/mm)was less
in mCAT mice (0.50.03 mg/mm; P<0.01 versus WT HFHS).
While systolic function was preserved in HFHS-fed mice,
there was LV diastolic dysfunction as assessed by both
transmitral ﬂow velocity (E/A; Table) and myocardial peak
early diastolic velocity (Em; Table; Figure 8B). The HFHS diet-
induced decreases in both E/A and Em were prevented in
mCAT mice (Table; Figure 8B). Thus, in mCAT mice the
structural and functional effects of HFHS feeding were
ameliorated.
Discussion
In the present study we show that in mice with diet-induced
obesity mitochondrial ROS impair mitochondrial electron
transport via irreversible OPTMs of complex I and reversible
cysteine OPTMs of complex II. We further demonstrate that
reversible oxidation of complex II subunit B Cys100 and
Cys103, for which we previously identiﬁed OPTMs in HFHS-fed
mice,9 causes reversible inhibition of enzyme activity. Finally,
we show that in HFHS-fed mice scavenging mitochondrial ROS
inhibits cardiac hypertrophy and improves diastolic function.
HFHS Feeding Causes Irreversible Inhibition of
Complex I and Reversible Inhibition of Complex II
We previously showed that HFHS feeding for 8 months
caused inhibition of complex I that was not reversed by DTT
ex vivo.9 In contrast, inhibition of complex II was partially
reversed by DTT ex vivo and associated with reversible
cysteine OPTMs as identiﬁed by iodoacetamide-based cys-
teine-reactive tandem mass tag labeling10 and with a biotin
switch assay.9,18 In the present study, mice were fed the
Figure 7. Oxidation of succinate dehydrogenase B (SDHB) Cys100 and Cys103 inhibits mitochondrial
complex II activity. Exposure of cells to high-glucose/high-palmitate (HGHP) media (14 hours) decreased
complex II activity, measured as per Figure 4, in HEK 293T cells. SDHB in which Cys100Ser (C100S),
Cys103Ser (C103S), or Cys115Ser (C115S) was mutated to a redox-insensitive serine was expressed in
HEK 293T cells, and complex II activity was measured after exposure to HGHP media. A, HGHP treatment
decreased complex II activity in HEK cells transfected with empty vector (CTRL), and activity was restored
after incubation of cell lysate with dithiothreitol (DTT; 5 mmol/L). B, Expression of the SDHB C100S mutant
prevents the HGHP-mediated decrease in complex II activity. C, Expression of the SDHB C103S mutant
prevents the HGHP-mediated decrease in complex II activity. D, Expression of the SDHB C115S mutant has
no effect on the HGHP-mediated decrease in complex II activity. Values are meanSEM; n=3 to 4; *P<0.05
vs CTRL; #P<0.05 vs CTRL+HGHP; ##P<0.01 vs CTRL+HGHP.
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HFHS diet for only 4 months, which resulted in mitochondrial
dysfunction and a cardiac phenotype that was similar to that
observed at 8 months except that the inhibition of complex II
at 4 months was fully reversible ex vivo by DTT but only
partially reversible at 8 months.9 As with HFHS feeding for
8 months, there was no change in the expression of electron
transport chain proteins. Taken together, these observations
suggest that complex II dysfunction with HFHS feeding is
caused initially (eg, 4 months) by ≥1 reversible cysteine
OPTM. With more prolonged exposure (eg, 8 months) to HFHS
diet, this reversible OPTM may be superseded by irreversible
and/or noncysteine OPTMs.
mCAT Prevents HFHS-Induced Complex I and II
Dysfunction
HFHS-induced dysfunction of both complexes I and II, as
reﬂected by respiration and ATP production, was completely
prevented by mCAT in vivo, and subsequent exposure to DTT
ex vivo had no further effect. Based on the ability of mCAT to
protect mitochondrial function, we conclude that ROS play an
important role in mediating mitochondrial dysfunction in this
model of MHD.
We cannot determine the relative contributions of complex
I and II OPTMs to overall mitochondrial dysfunction, nor can
we exclude a role for OPTMs of other proteins involved in
electron transport chain function. For example, complex V is
inhibited by glutathiolation in the setting of chronic heart
failure.19 However, because DTT did not increase complex I
substrate–mediated ATP production, which also requires
complex V, the effects of DTT and mCAT are unlikely to be
caused by increased complex V activity. Likewise, although
uncoupling protein 3 can be regulated by oxidative cysteine
modiﬁcation,20 we found that proton leak-driven respiration
for both complex I and complex II was decreased in HFHS-fed
mice and restored by mCAT. Thus, in contrast to genetic
models of obesity and/or diabetes (ob/ob and db/db
mice),21,22 uncoupling does not play a major role in HFHS-
fed mice.
The mCAT mouse used in this study is also protected from
the cardiac effects of aortic constriction23 and aging.11 In
mice with reduced expression of mitofusin II, mitochondrial
function and cardiac phenotype were also improved by mCAT
expression sufﬁcient to normalize mitochondrial ROS,
although supersuppression of mitochondrial ROS by a higher
level of mCAT was deleterious.24 In this regard, the beneﬁcial
effects of mCAT on mitochondrial function in the present
study were associated with normalization of mitochondrial
ROS measured ex vivo in isolated mitochondria. While this
observation suggests that mitochondrial ROS are suppressed
in the mCAT mouse, it does not allow conclusions about the
extent of its suppression in vivo.
Cysteine OPTM Inhibit Complex II Function
Complex II, which couples the oxidation of succinate to
fumarate in the matrix with the reduction of ubiquinone in the
membrane,25 consists of 4 nuclear-encoded proteins—SDH
Table. Body and Organ Weights and Echocardiographic Parameters
WT/CD WT/HFHS mCAT/CD mCAT/HFHS
Body and organ weights
Body weight, g 29.53.1 47.51.0* 29.54.2 46.92.5†
Heart weight, mg 116.54.0 144.67.4* 131.613.0 151.312.7
Tibia length, mm 18.20.4 17.90.1 17.70.3 18.00.3
Heart weight/body weight, mg/g 4.120.37 3.050.13 4.560.24 3.220.16†
Heart weight/tibia length, mg/mm 6.50.3 8.10.4* 7.40.6 7.90.5
Echocardiographic measurements
LV EDD 2.870.03 2.930.03 2.900.06 3.080.04
LV ESD 1.170.02 1.200.01 1.150.03 1.240.02
FS 59.50.3 59.40.6 60.50.5 60.00.5
TWT 1.530.04 1.800.06* 1.500.04 1.590.06‡
E/A 1.660.04 1.240.07§ 1.740.06 1.820.07 ׀׀
Em 25.60.8 17.90.9§ 26.00.7 25.10.3 ׀׀
E/Em 28.80.8 43.82.0** 28.82.8 32.81.0##
Values are meanSEM; n=4 to 7. CD indicates control diet; E/A, ratio of early-to-late diastolic mitral inﬂow velocity; E/Em, ratio of peak early mitral inﬂow velocity to myocardial peak early
diastolic velocity; EDD, end-diastolic dimension; Em, myocardial peak early diastolic velocity; ESD, end-systolic dimension; FS, fractional shortening; HFHS, high-fat high-sucrose diet; LV,
left ventricular; mCAT, mitochondrial catalase; TWT, total wall thickness; WT, wild-type.
*P<0.01 vs WT CD; †P<0.01 vs mCAT CD; ‡P<0.05 vs WT HFHS; §P<0.001 vs WT/CD; ׀׀ P<0.005 vs WT HFHS.
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subunits A, B, C, and D. SDHA and SDHB are exposed to the
matrix, while SDHC and SDHD are in the inner membrane.26 To
evaluate the role of cysteine OPTM in regulating complex II
function, we used HEK-293 cells in culture. In this system,
exposure to both H2O2 and high concentrations of glucose and
palmitate in the media inhibited complex II activity, and
importantly, the inhibition was reversed by the subsequent
ex vivo addition of DTT, thus replicating the ability of DTT to
restore complex II function in mitochondria from HFHS-fed
mice. We previously identiﬁed Cys100, Cys103, and Cys115 in
SDHB as undergoing reversible oxidative modiﬁcation in HFHS-
fed mice.9 While the functional signiﬁcance of these OPTM is
not known, all 3 of these cysteines are components of the 2Fe-
2S iron–sulfur cluster, which is critical for enzyme activity.27
The cysteine-to-serine mutation of either Cys100 or
Cys103 fully protected complex II from the H2O2-induced
decrease in activity in HEK cells. In contrast, mutation of
Cys115 to serine had no effect. Given the roles of Cys100 and
Cys103 in the complex II iron–sulfur cluster, it is likely that
their oxidative modiﬁcation leads to changes in conformation
of the cluster that affect its ability to bind iron and/or
participate in electron transfer. To our knowledge, this is the
ﬁrst demonstration that Cys100 and Cys103 play a critical
role in redox regulation of complex II function. Incubation in
HGHP medium caused inhibition of complex II activity, was
reversed by ex vivo exposure to DTT and was prevented in
cells overexpressing the Cys100 and Cys103 mutants—thus
replicating the effects of H2O2. This observation in an in vitro
model of nutrient excess thus supports the relevance of this
mechanism to the mitochondrial dysfunction we observed in
HFHS-fed mice.
Of note, mutations of some, but not all, cysteines involved
in the iron–sulfur cluster of fumarate reductase, an enzyme
that is related to SDH, decreased enzyme activity and altered
growth in bacteria.27 We previously observed reversible
oxidation of SDHA Cys89 in HFHS-fed mice.9 However,
S-glutathiolation of rat SDHA at Cys90 (Cys89 in the mouse
proteome) increases complex II activity,28 and therefore is not
likely to be the cause of decreased complex II activity with
HFHS feeding.
A limitation of this study is that it does not address the
relative importance of impaired complex II activity in medi-
ating overall mitochondrial dysfunction in this model. The
importance of complex II for cardiac function has been well
established under conditions of ischemia–reperfusion, where
succinate accumulation drives increased mitochondrial
ROS,29 and in human genetic cardiomyopathies resulting
from complex II deﬁciency.30 Modeling of succinate dehydro-
genase ﬂux supports the notion of its important contribution
to cardiac ATP generation.31 Additionally, while pyruvate
levels are not thought to be increased in cardiac hypertrophy,
succinate is increased, suggesting that its use may be
increased.32
Mitochondrial ROS Mediate Cardiac Dysfunction
in Obesity-Related MHD
Our observation of increased mitochondrial ROS produc-
tion with an HFHS diet is consistent with several prior
reports.5,33–35 A possible role for ROS in mediating myocar-
dial hypertrophy and diastolic dysfunction with HFHS feeding
was raised by our initial study in which polyphenols effectively
prevented the cardiac phenotype.8 However, polyphenols
have pleiotropic actions that preclude this conclusion. In the
present study, mCAT inhibited the HFHS feeding–associated
development of LV hypertrophy and largely prevented dias-
tolic dysfunction. Heart size assessed as heart weight
normalized to tibia length or LV wall thickness by echocar-
diography tended to be larger in mCAT (versus WT mice) fed
Figure 8. Left ventricular hypertrophy and diastolic dysfunction
induced by high-fat high-sucrose (HFHS) diet feeding for
4 months is prevented in mitochondrial catalase (mCAT) mice.
A, Total wall thickness. B, Myocardial peak early diastolic velocity
(Em). Values are meanSEM; n=4 to 5; **P<0.01 vs wild-type
(WT) control diet (CD); ***P<0.001 vs WT CD; #P<0.05 vs WT
HFHS; ###P<0.001 vs WT HFHS.
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the CD. However, the HFHS-induced increases in both heart
weight and wall thickness were decreased in mCAT (versus
WT) mice. Likewise, HFHS diet–induced LV diastolic dysfunc-
tion was improved in mCAT (versus WT) mice as assessed by
both transmitral and tissue Doppler examinations. These
ﬁnding, taken together with the demonstration that mito-
chondrial ROS production is increased with HFHS feeding,
suggests that mitochondrial ROS plays a key role in mediating
these key aspects of the cardiac phenotype in MHD.
The mechanism by which mitochondrial ROS mediate LV
hypertrophy and diastolic dysfunction in HFHS-fed mice
remains to be determined (Figure 9). It is possible that the
mitochondrial effects of ROS shown here contribute to
diastolic dysfunction by decreasing the supply of ATP
necessary for sarcoplasmic reticulum Ca2+-ATPase–mediated
reuptake of calcium into the sarcoplasmic reticulum.36
Because H2O2 is freely permeable through biologic mem-
branes, mitochondrial ROS may also mediate LV structure and
function via extramitochondrial signaling cascades that could
affect multiple targets and pathways involved in the regulation
of myocyte growth, ﬁbrosis, and excitation–contraction cou-
pling.23,24,37,38 In addition, mCAT mice are protected from
insulin resistance induced by a high-fat diet,39 which might
correct the delivery of energy substrates. Our ﬁndings suggest
that these features of cardiac phenotype exhibit a plasticity
that is mediated by diet-related metabolic factors and that
may be ameliorated by dietary intervention.
Conclusion
Catalase targeted to the mitochondria ameliorated both
mitochondrial dysfunction and the cardiac phenotype (LV
hypertrophy and diastolic dysfunction) caused by HFHS
feeding. These structural and functional effects were asso-
ciated with protection of complexes I and II from OPTMs,
including reversible OPTMs of complex II that mediate
complex II dysfunction in vitro. In this regard, we identiﬁed
2 cysteines in SDHB (Cys100 and Cys103) that regulate
complex II function in a redox-dependent manner. These
ﬁndings suggest that efforts to decrease mitochondrial ROS
or their effects on target proteins may be of value in the
therapy of MHD.
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function. HFHS diet feeding was associated with impaired ATP
production and increased reactive oxygen species (ROS) gener-
ation in cardiac mitochondria. Decreased ATP production may
contribute to diastolic dysfunction by limiting the function of
highly ATP-dependent enzymes such as sarcoplasmic reticulum
Ca2+ ATPase (SERCA) that are needed for normal diastolic calcium
homeostasis. ROS may also trigger multiple extramitochondrial
signaling cascades involved in myocyte hypertrophy and the
regulation of diastolic function.
DOI: 10.1161/JAHA.115.002555 Journal of the American Heart Association 12















 at UNIV OF ADELAIDE on May 8, 2016http://jaha.ahajournals.org/Downloaded from 
4. Ayalon N, Gopal DM, Mooney DM, Simonetti JS, Grossman JR, Dwivedi A,
Donohue C, Perez AJ, Downing J, Gokce N, Miller EJ, Liang CS, Apovian CM,
Colucci WS, Ho JE. Preclinical left ventricular diastolic dysfunction in metabolic
syndrome. Am J Cardiol. 2014;114:838–842.
5. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy.
Diabetologia. 2014;57:660–671.
6. Huynh K, Bernardo BC, McMullen JR, Ritchie RH. Diabetic cardiomyopathy:
mechanisms and new treatment strategies targeting antioxidant signaling
pathways. Pharmacol Ther. 2014;142:375–415.
7. Scheuermann-Freestone M, Madsen PL, Manners D, Blamire AM, Buckingham
RE, Styles P, Radda GK, Neubauer S, Clarke K. Abnormal cardiac and skeletal
muscle energy metabolism in patients with type 2 diabetes. Circulation.
2003;107:3040–3046.
8. Qin F, Siwik DA, Luptak I, Hou X, Wang L, Higuchi A, Weisbrod RM, Ouchi N, Tu
VH, Calamaras TD, Miller EJ, Verbeuren TJ, Walsh K, Cohen RA, Colucci WS.
The polyphenols resveratrol and S17834 prevent the structural and functional
sequelae of diet-induced metabolic heart disease in mice. Circulation.
2012;125:1757–1764, S1751–1756.
9. Sverdlov AL, Elezaby A, Behring JB, Bachschmid MM, Luptak I, Tu VH, Siwik DA,
Miller EJ, Liesa M, Shirihai OS, Pimentel DR, Cohen RA, Colucci WS. High fat,
high sucrose diet causes cardiac mitochondrial dysfunction due in part to
oxidative post-translational modiﬁcation of mitochondrial complex II. J Mol Cell
Cardiol. 2015;78:165–173.
10. Behring JB, Kumar V, Whelan SA, Chauhan P, Siwik DA, Costello CE, Colucci
WS, Cohen RA, McComb ME, Bachschmid MM. Does reversible cysteine
oxidation link the western diet to cardiac dysfunction? FASEB J.
2014;28:1975–1987.
11. Schriner SE, Linford NJ, Martin GM, Treuting P, Ogburn CE, Emond M, Coskun
PE, Ladiges W, Wolf N, Van Remmen H, Wallace DC, Rabinovitch PS. Extension
of murine life span by overexpression of catalase targeted to mitochondria.
Science. 2005;308:1909–1911.
12. Weisbrod RM, Shiang T, Al Sayah L, Fry JL, Bajpai S, Reinhart-King CA, Lob HE,
Santhanam L, Mitchell G, Cohen RA, Seta F. Arterial stiffening precedes systolic
hypertension in diet-induced obesity. Hypertension. 2013;62:1105–1110.
13. Schaefer A, Klein G, Brand B, Lippolt P, Drexler H, Meyer GP. Evaluation of left
ventricular diastolic function by pulsed Doppler tissue imaging in mice. J Am
Soc Echocardiogr. 2003;16:1144–1149.
14. Elezaby A, Sverdlov AL, Tu VH, Soni K, Luptak I, Qin F, Liesa M, Shirihai OS,
Rimer J, Schaffer JE, Wilson SC, Edward JM. Mitochondrial remodeling in mice
with cardiomyocyte-speciﬁc lipid overload. J Mol Cell Cardiol. 2015;79:275–
283.
15. Liesa M, Luptak I, Qin F, Hyde BB, Sahin E, Siwik DA, Zhu Z, Pimentel DR, Xu
XJ, Ruderman NB, Huffman KD, Doctrow SR, Richey L, Colucci WS, Shirihai OS.
Mitochondrial transporter ATP binding cassette mitochondrial erythroid is a
novel gene required for cardiac recovery after ischemia/reperfusion. Circu-
lation. 2011;124:806–813.
16. Sahin E, Colla S, Liesa M, Moslehi J, Muller FL, Guo M, Cooper M, Kotton D,
Fabian AJ, Walkey C, Maser RS, Tonon G, Foerster F, Xiong R, Wang YA, Shukla
SA, Jaskelioff M, Martin ES, Heffernan TP, Protopopov A, Ivanova E, Mahoney
JE, Kost-Alimova M, Perry SR, Bronson R, Liao R, Mulligan R, Shirihai OS, Chin
L, DePinho RA. Telomere dysfunction induces metabolic and mitochondrial
compromise. Nature. 2011;470:359–365.
17. Shao D, Fry JL, Han J, Hou X, Pimentel DR, Matsui R, Cohen RA, Bachschmid
MM. A redox-resistant sirtuin-1 mutant protects against hepatic metabolic and
oxidant stress. J Biol Chem. 2014;289:7293–7306.
18. Pimentel D, Haeussler DJ, Matsui R, Burgoyne JR, Cohen RA, Bachschmid MM.
Regulation of cell physiology and pathology by protein S-glutathionylation:
lessons learned from the cardiovascular system. Antioxid Redox Signal.
2012;16:524–542.
19. Wang SB, Foster DB, Rucker J, O’Rourke B, Kass DA, Van Eyk JE. Redox
regulation of mitochondrial ATP synthase: implications for cardiac resynchro-
nization therapy. Circ Res. 2011;109:750–757.
20. Mailloux RJ, Seifert EL, Bouillaud F, Aguer C, Collins S, Harper ME.
Glutathionylation acts as a control switch for uncoupling proteins UCP2 and
UCP3. J Biol Chem. 2011;286:21865–21875.
21. Boudina S, Sena S, O’Neill BT, Tathireddy P, Young ME, Abel ED. Reduced
mitochondrial oxidative capacity and increased mitochondrial uncoupling
impair myocardial energetics in obesity. Circulation. 2005;112:2686–2695.
22. Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, Aziz S, Johnson JI,
Bugger H, Zaha VG, Abel ED. Mitochondrial energetics in the heart in obesity-
related diabetes: direct evidence for increased uncoupled respiration and
activation of uncoupling proteins. Diabetes. 2007;56:2457–2466.
23. Dai DF, Hsieh EJ, Liu Y, Chen T, Beyer RP, Chin MT, MacCoss MJ, Rabinovitch
PS. Mitochondrial proteome remodelling in pressure overload-induced heart
failure: the role of mitochondrial oxidative stress. Cardiovasc Res.
2012;93:79–88.
24. Song M, Chen Y, Gong G, Murphy E, Rabinovitch PS, Dorn GW II. Super-
suppression of mitochondrial reactive oxygen species signaling impairs
compensatory autophagy in primary mitophagic cardiomyopathy. Circ Res.
2014;115:348–353.
25. Wojtovich AP, Smith CO, Haynes CM, Nehrke KW, Brookes PS. Physiological
consequences of complex II inhibition for aging, disease, and the mKATP
channel. Biochim Biophys Acta. 2013;1827:598–611.
26. Yankovskaya V, Horseﬁeld R, Tornroth S, Luna-Chavez C, Miyoshi H, Leger C,
Byrne B, Cecchini G, Iwata S. Architecture of succinate dehydrogenase and
reactive oxygen species generation. Science. 2003;299:700–704.
27. Werth MT, Cecchini G, Manodori A, Ackrell BA, Schroder I, Gunsalus RP,
Johnson MK. Site-directed mutagenesis of conserved cysteine residues in
Escherichia coli fumarate reductase: modiﬁcation of the spectroscopic and
electrochemical properties of the [2Fe-2S] cluster. Proc Natl Acad Sci USA.
1990;87:8965–8969.
28. Chen YR, Chen CL, Pfeiffer DR, Zweier JL. Mitochondrial complex II in the post-
ischemic heart: oxidative injury and the role of protein S-glutathionylation. J
Biol Chem. 2007;282:32640–32654.
29. Chouchani ET, Pell VR, Gaude E, Aksentijevic D, Sundier SY, Robb EL, Logan A,
Nadtochiy SM, Ord EN, Smith AC, Eyassu F, Shirley R, Hu CH, Dare AJ, James
AM, Rogatti S, Hartley RC, Eaton S, Costa AS, Brookes PS, Davidson SM,
Duchen MR, Saeb-Parsy K, Shattock MJ, Robinson AJ, Work LM, Frezza C, Krieg
T, Murphy MP. Ischaemic accumulation of succinate controls reperfusion
injury through mitochondrial ROS. Nature. 2014;515:431–435.
30. Reichmann H, Angelini C. Single muscle ﬁbre analyses in 2 brothers with
succinate dehydrogenase deﬁciency. Eur Neurol. 1994;34:95–98.
31. Smith AC, Robinson AJ. A metabolic model of the mitochondrion and its use in
modelling diseases of the tricarboxylic acid cycle. BMC Syst Biol. 2011;5:102.
32. Kolwicz SC Jr, Tian R. Glucose metabolism and cardiac hypertrophy.
Cardiovasc Res. 2011;90:194–201.
33. Ilkun O, Boudina S. Cardiac dysfunction and oxidative stress in the metabolic
syndrome: an update on antioxidant therapies. Curr Pharm Des.
2013;19:4806–4817.
34. Mellor KM, Ritchie RH, Delbridge LM. Reactive oxygen species and insulin-
resistant cardiomyopathy. Clin Exp Pharmacol Physiol. 2010;37:222–228.
35. Roul D, Recchia FA. Metabolic alterations induce oxidative stress in diabetic
and failing hearts: different pathways, same outcome. Antioxid Redox Signal.
2015;22:1502–1514.
36. Kammermeier H. High energy phosphate of the myocardium: concentration
versus free energy change. Basic Res Cardiol. 1987;82(suppl 2):31–36.
37. Qin F, Siwik DA, Pimentel DR, Morgan RJ, Biolo A, Tu VH, Kang YJ, Cohen RA,
Colucci WS. Cytosolic H2O2 mediates hypertrophy, apoptosis, and decreased
SERCA activity in mice with chronic hemodynamic overload. Am J Physiol Heart
Circ Physiol. 2014;306:H1453–H1463.
38. Sawyer DB, Sverdlov AL, Colucci WS. Chapter 8—oxidative stress in heart
failure. In: Mann DL, Felker MG, eds. Heart Failure: A Companion to
Braunwald’s Heart Disease. 3rd ed. Philadelphia: W.B. Saunders; 2016:127–
139.
39. Anderson EJ, Lustig ME, Boyle KE, Woodlief TL, Kane DA, Lin CT, Price JW III,
Kang L, Rabinovitch PS, Szeto HH, Houmard JA, Cortright RN, Wasserman DH,
Neufer PD. Mitochondrial H2O2 emission and cellular redox state link excess
fat intake to insulin resistance in both rodents and humans. J Clin Invest.
2009;119:573–581.
DOI: 10.1161/JAHA.115.002555 Journal of the American Heart Association 13















 at UNIV OF ADELAIDE on May 8, 2016http://jaha.ahajournals.org/Downloaded from 
Supplemental Material 
 
Table S1. Composition of HFHS and control diets. D09071702 is HFHS diet and D09071703 
is control diet. 
 
 
Table S2. Expression of informative subunits from each of the 5 electron transport chain 
complexes as measured by immunoblot. 
 WT / CD WT / HFHS mCAT / CD mCAT / HFHS 
Protein (ETC complex)     
NDUFB8 (Complex I) 1.00 ± 0.03 0.90 ± 0.04 1.0 ± 0.09 0.82 ± 0.07 
SDHB (Complex II) 1.00 ± 0.05 0.84 ± 0.04 0.79 ± 0.05 0.83 ± 0.09 
UQCRC2 (Complex III) 1.00 ± 0.14 0.95 ± 0.07 1.10 ± 0.05 1.00 ± 0.09 
MTCO1 (Complex IV) 1.00 ± 0.09 0.90 ± 0.07 0.84 ± 0.07 0.91 ± 0.18 
ATP5A (Complex V) 1.00 ± 0.07 0.94 ± 0.04 0.90 ± 0.03 0.84 ± 0.09 
 
Values are normalized to VDAC and reported relative to WT / CD. Values are mean ± SEM. For 
all subunits, P = NS for WT / HFHS vs WT / CD and for mCAT / HFHS vs mCAT / CD.   
 Figure S1. Both WT and mCAT mice on HFHS diet exhibit the same degree of total body 
weight gain. (n=4-5 per group). 
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 Figure S2. Respiratory control ratios (RCR) obtained during oxygen consumption 
measurements. HFHS diet had no effect on RCR values (obtained by dividing State III by State 
IV oxygen consumption). 
 










 Figure S3. Exposure to the reducing agent dithiothreitol (DTT, 5 mM) ex vivo corrects ATP 
synthesis for complex II, but not complex I, substrates. Panel A. Complex I substrate-driven 
ATP synthesis rate (5 mM pyruvate + 5mM malate); Panel B. Complex II substrate-driven ATP 




 Figure S4. Neither complex I nor Complex II substrate-driven ATP synthesis rates in 
cardiac mitochondria from mCAT mice fed a HFHS are effected ex-vivo by DTT (5 mM). 
A) Complex I substrate-driven ATP synthesis rate (5 mM pyruvate + 5mM malate); B) Complex 
II substrate-driven ATP synthesis rate (5 mM succinate + 2µM rotenone). 
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 Figure S2. Respiratory control ratios (RCR) obtained during oxygen consumption 
measurements. HFHS diet had no effect on RCR values (obtained by dividing State III by State 
IV oxygen consumption). 
 










 Figure S3. Exposure to the reducing agent dithiothreitol (DTT, 5 mM) ex vivo corrects ATP 
synthesis for complex II, but not complex I, substrates. Panel A. Complex I substrate-driven 
ATP synthesis rate (5 mM pyruvate + 5mM malate); Panel B. Complex II substrate-driven ATP 




 Figure S4. Neither complex I nor Complex II substrate-driven ATP synthesis rates in 
cardiac mitochondria from mCAT mice fed a HFHS are effected ex-vivo by DTT (5 mM). 
A) Complex I substrate-driven ATP synthesis rate (5 mM pyruvate + 5mM malate); B) Complex 
II substrate-driven ATP synthesis rate (5 mM succinate + 2µM rotenone). 
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